Profile
Nelson Chau worked as a Vice President at LogicBio Therapeutics, Inc. from 2017 to 2021.
Prior to that, he worked as a Vice President at Translate Bio, Inc. and as a Director of Research at Regulus Therapeutics, Inc. Mr. Chau holds a doctorate degree from The Johns Hopkins University School of Medicine.
Former positions of Nelson Chau
Companies | Position | End |
---|---|---|
LOGICBIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-04-30 |
REGULUS THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | - |
TRANSLATE BIO, INC. | Corporate Officer/Principal | - |
Training of Nelson Chau
The Johns Hopkins University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
Private companies | 2 |
---|---|
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Nelson Chau